Table 2 Analysis of the independent Validation Series A risk group predictions generated using the 160-gene prognostic signature
Stage | No. Patients | Kaplan Meier Analysis (160-gene signature assigned high/low risk categories) | Cox Proportional Hazards Regression (160-gene signature assigned high/low risk categories) | Receiver Operator Curve analysis (association with 5-year DSS) | |||
|---|---|---|---|---|---|---|---|
Univariate P-value | Hazard Ratio (95 % CI) | Multivariate P-value | Hazard Ratio (95 % CI) | P-value | AUC (95 % CI) | ||
I & II | 264 | <0.0001 | 2.26 (1.46 to 3.50) | <0.0001 | 2.80 (1.83 to 4.28) | 0.0004 | 0.66 (0.59 to 0.71) |
I | 201 | 0.0008 | 2.23 (1.30 to 3.84) | <0.0001 | 3.00 (1.78 to 5.08) | 0.0002 | 0.68 (0.61 to 0.75) |
IA | 93 | 0.18 | 1.76 (0.70 to 4.47) | 0.045 | 2.65 (1.029 to 6.83) | 0.019 | 0.69 (0.59 to 0.78) |
IB | 97 | 0.0008 | 2.79 (1.38 to 5.64) | <0.0001 | 5.44 (2.48 to 11.97) | <0.0001 | 0.75 (0.65 to 0.83) |
II | 63 | 0.048 | 2.00 (0.98 to 4.14) | 0.042 | 2.20 (1.034 to 4.69) | 0.56 | 0.56 (0.42 to 0.70) |
IIA | 13 | 0.0097 | 5.57(1.59 to 19.59) | 0.048 | 28.21 (1.048 to 759.30) | 1.0 | 0.50 (0.17 to 0.83) |
IIB | 44 | 0.42 | 1.47 (0.56 to 3.83) | 0.48 | 1.44 (0.52 to 4.027) | 0.57 | 0.57 (0.40 to 0.58) |